171 related articles for article (PubMed ID: 9027742)
1. Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene.
Levy AP; Levy NS; Iliopoulos O; Jiang C; Kaplin WG; Goldberg MA
Kidney Int; 1997 Feb; 51(2):575-8. PubMed ID: 9027742
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
3. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
4. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
5. The molecular basis of von Hippel-Lindau disease.
Iliopoulos O; Kaelin WG
Mol Med; 1997 May; 3(5):289-93. PubMed ID: 9205944
[No Abstract] [Full Text] [Related]
6. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein.
Levy AP; Levy NS; Goldberg MA
J Biol Chem; 1996 Oct; 271(41):25492-7. PubMed ID: 8810320
[TBL] [Abstract][Full Text] [Related]
8. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.
Mukhopadhyay D; Knebelmann B; Cohen HT; Ananth S; Sukhatme VP
Mol Cell Biol; 1997 Sep; 17(9):5629-39. PubMed ID: 9271438
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Marti HH; Plate KH
Blood; 1998 Nov; 92(9):3388-93. PubMed ID: 9787178
[TBL] [Abstract][Full Text] [Related]
10. von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis.
Jones MK; Szabó IL; Kawanaka H; Husain SS; Tarnawski AS
FASEB J; 2002 Feb; 16(2):264-6. PubMed ID: 11772947
[TBL] [Abstract][Full Text] [Related]
11. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
12. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
13. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
14. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
EMBO J; 2003 Apr; 22(8):1857-67. PubMed ID: 12682018
[TBL] [Abstract][Full Text] [Related]
15. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.
Barry RE; Krek W
Trends Mol Med; 2004 Sep; 10(9):466-72. PubMed ID: 15350900
[No Abstract] [Full Text] [Related]
16. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos O; Levy AP; Jiang C; Kaelin WG; Goldberg MA
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10595-9. PubMed ID: 8855223
[TBL] [Abstract][Full Text] [Related]
17. Cancer. Many vessels, faulty gene.
Kaelin WG
Nature; 1999 May; 399(6733):203-4. PubMed ID: 10353237
[No Abstract] [Full Text] [Related]
18. The von Hippel-Lindau tumor suppressor protein.
Ivan M; Kaelin WG
Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
[TBL] [Abstract][Full Text] [Related]
19. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
Pugh CW; Ratcliffe PJ
Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560
[TBL] [Abstract][Full Text] [Related]
20. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
